Sirnaomics Ltd. operates as a holding company, which engages in research and development of clinical drugs. It is also involved in the development and manufacturing of RNA interference therapeutics. Its product pipeline includes STP705, STP707, RV-1730, and GalAhead. The company was founded by Yang Lu on October 15, 2020 and is headquartered in Hong Kong.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company